Stomach/Duodenum News

To celebrate World Digestive Health Day on May 29, the World Gastroenterology Organization launched a campaign, “Your Digestive Health: Make It A Priority,” to boost awareness on the vital role the digestive system plays in overall health.

Most patients undergoing colonoscopy after diverticulitis had low risk for colorectal cancer, except those with complicated diverticulitis, whose risk was nearly four times greater than the screening population, according to research.

Women with obesity who undergo bariatric surgery and have higher levels of insulin have a lower risk for breast cancer than women who do not undergo surgery, according to findings published in JAMA Surgery.

Endoscopic ablation of the gastric fundus reduced ghrelin, the primary hunger hormone, and resulted in significant weight loss among a small cohort of female patients with obesity, according to research.

In honor of International Celiac Awareness Day, landmarks in the U.S. and around the globe will once again light up on May 16 to promote the #ShineALightOnCeliac social media campaign to encourge awareness and additional research.

Children diagnosed with celiac disease and treated through a statewide screening program experienced improvements in initially unrecognized symptoms and quality of life, as well as greater adherence to a gluten-free diet, research showed.

Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis, according to data.

Adults with type 2 diabetes have a reduction in overall health care costs after bariatric surgery, regardless of whether they underwent gastric bypass or sleeve gastrectomy, according to study findings published in Obesity.

Once-weekly glucagon-like peptide-1 receptor agonist use was associated with a “significantly higher prevalence” of increased residual gastric content among fasted patients undergoing elective procedures under anesthesia, research showed.

GLP-1 receptor agonists come with known adverse events — some common and some rare — but recent reports by the public of alopecia and suicidal ideation have the FDA investigating.